WungkiParkMD

PubMed

• Concordance in Oncogenic Alterations Between the Primary Tumor and Advanced Disease: Insights Into the Heterogeneity of Intrahepatic Cholangiocarcinoma.
  Harding, J., Sarah M McIntyre, William A Preston, Henry Walch, Jeremy Sharib, Ritika Kundra, Carlie Sigel, Michael E Lidsky, Peter J Allen, Michael A Morse, Wei Chen, ...> ;JCO Precision Oncology. 2024 Feb 1
• 1 citations
  KRASinhibition in pancreatic cancer: Fas expression facilitates immune clearance.
  Celine Yeh, Wungki Park, Rona Yaeger> ;Developmental Cell. 2023 Sep 11
• 2 citations
  Genomic Profiling Reveals Germline Predisposition and Homologous Recombination Deficiency in Pancreatic Acinar Cell Carcinoma.
  Diana Mandelker, Antonio Marra, Binbin Zheng-Lin, Pier Selenica, Juan Blanco-Heredia, Yingjie Zhu, Andrea Gazzo, Donna Wong, Zarina Yelskaya, Vikas Rai, Joshua Somar, ...> ;Journal of Clinical Oncology. 2023 Nov 20
• 3 citations
  Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational bur...
  Vaia Florou, Charalampos S Floudas, Asaf Maoz, Abdul Rafeh Naqash, Carter Norton, Aik Choon Tan, Ethan S Sokol, Garrett Frampton, Heloisa P Soares, Sonam Puri, Umang S...> ;Journal for Immunotherapy of Cancer. 2023 Aug 1
• 164 citations
  Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer.
  Luis A Rojas, Zachary Sethna, Kevin C Soares, Cristina Olcese, Nan Pang, Erin Patterson, Jayon Lihm, Nicholas Ceglia, Pablo Guasp, Alexander Chu, Rebecca Yu, Adrienne ...> ;Nature. 2023 Jun 1
• 2 citations
  Pancreatic Cancer:Targeted Therapy and Beyond.
  Fergus Keane, Catherine A O'Connor, Wungki Park, Thomas Seufferlein, Eileen M O'Reilly> ;Cancers. 2023 May 28
• Dramatic, durable response to therapy in gBRCA2-mutated pancreas neuroendocrine carcinoma: opportunity and challenge.
  Fergus Keane, Raazi Bajwa, Pier Selenica, Wungki Park, Michael H Roehrl, Jorge S Reis-Filho, Diana Mandelker, Eileen M O'Reilly> ;NPJ Precision Oncology. 2023 Apr 22
• 2 citations
  Durable Response after Olaparib Treatment for Perihilar Cholangiocarcinoma with Germline BRCA2 Mutation.
  Bruno Almeida Costa, Paulino Tallón de Lara, Wungki Park, Fergus Keane, James J Harding, Danny N Khalil> ;Oncology Research and Treatment. 2023 Jan 1
• 4 citations
  Methylation Analyses Reveal Promoter Hypermethylation as a Rare Cause of "Second Hit" in Germline BRCA1-Associated Pancreatic Ductal Adenocarcinoma.
  Binbin Zheng-Lin, Michael Rainone, Anna M Varghese, Kenneth H Yu, Wungki Park, Michael Berger, Miika Mehine, Joanne Chou, Marinela Capanu, Diana Mandelker, Zsofia K St...> ;Molecular Diagnosis & Therapy. 2022 Nov 1
• 9 citations
  Stereotactic ablative radiation for pancreatic cancer on a 1.5 Telsa magnetic resonance-linac system.
  Kathryn R Tringale, Neelam Tyagi, Marsha Reyngold, Paul B Romesser, Abraham Wu, Eileen M O'Reilly, Anna M Varghese, Paola Godoy Scripes, Danny N Khalil, Wungki Park, K...> ;Physics and Imaging in Radiation Oncology. 2022 Oct 1
• 2 citations
  Biomarker analysis from a phase II multi-institutional study of nivolumab in patients with advanced refractory biliary tract cancer.
  Dae Won Kim, Vincent Chung, Olatunji B Alese, Bassel F El-Rayes, Daneng Li, Wungki Park, Richard D Kim, Kim, Y., Kovari, B.> ;European Journal of Cancer. 2022 Nov 1
• 8 citations
  Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice.
  Wungki Park, Catherine A O'Connor, Chaitanya Bandlamudi, Daniella Forman, Joanne F Chou, Shigeaki Umeda, Marsha Reyngold, Anna M Varghese, Fergus Keane, Fiyinfolu Balo...> ;Clinical Cancer Research. 2022 Nov 1
• 2 citations
  Homologous Recombination Deficiency in Pancreatic Cancer: Poly (ADP-ribose) Polymerase Inhibition, Checkpoint Inhibition, or a Combination of Both?
  Fergus Keane, Wungki Park, Eileen M O'Reilly> ;JCO Precision Oncology. 2022 Jun 1
• 2 citations
  Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer.
  Kenneth H Yu, Jennifer Park, Avni Mittal, Ghassan K Abou-Alfa, Imane El Dika, Andrew S Epstein, David H Ilson, David P Kelsen, Geoffrey Y Ku, Jia Li, Wungki Park, Anna...> ;Cancer. 2022 Aug 1
• 3 citations
  A Review of Pancreatic Cancer-Reply.
  Wungki Park, Akhil Chawla, Eileen M O'Reilly> ;JAMA. 2021 Dec 21
• 490 citations
  Pancreatic Cancer: A Review
  Wungki Park, Akhil Chawla, Eileen M. O'Reilly> ;JAMA. 2021 Sep 7
• 31 citations
  Early-Onset Pancreas Cancer: Clinical Descriptors, Genomics, and Outcomes
  Singh, R., Anna M. Varghese, Isha Singh, Ritu Raj Singh, Siddharth Kunte, Joanne F. Chou, Marinela Capanu, Winston Wong, Maeve A. Lowery, Zsofia K. Stadler, Erin E. Sa...> ;Journal of the National Cancer Institute. 2021 Sep 4
• 15 citations
  Targeting DNA damage repair pathways in pancreas cancer
  Fionnuala Crowley, Wungki Park, Eileen M. O'Reilly> ;Cancer Metastasis Reviews. 2021 Aug 17
• 18 citations
  Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes.
  Parisa Momtaz, Catherine A. O’Connor, Joanne F. Chou, Marinela Capanu, Wungki Park, Chaitanya Bandlamudi, Michael F. Berger, David P. Kelsen, Sarah P. Suehnholz, Debya...> ;Cancer. 2021 Aug 5
• 12 citations
  Local Control and Survival After Induction Chemotherapy and Ablative Radiation Versus Resection for Pancreatic Ductal Adenocarcinoma With Vascular Involvement.
  Joshua S. Jolissaint, Marsha Reyngold, Jared Bassmann, Kenneth Seier, Mithat Gonen, Anna M. Varghese, Kenneth H. Yu, Wungki Park, Eileen M. O'Reilly, Vinod P. Balachan...> ;Annals of Surgery. 2021 Jul 16
• 19 citations
  Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics.
  Laura Mezquita, Isabel Ruth Preeshagul, Edouard Auclin, Diana Saravia, Lizza E.L. Hendriks, Hira Rizvi, Wungki Park, Ernest Nadal, Patricia Martin-Romano, Jose Carlos ...> ;European Journal of Cancer. 2021 Jul 1
• 86 citations
  Association of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer.
  Marsha Reyngold, Eileen M. O'Reilly, Anna M. Varghese, Megan Fiasconaro, M. Zinovoy, Paul B. Romesser, Abraham J. Wu, Carla Hajj, John J. Cuaron, R. Tuli, Lara Hilal, ...> ;JAMA Oncology. 2021 May 1
• 2 citations
  Leptomeningeal disease in pancreas ductal adenocarcinoma: A manifestation of longevity.
  Catherine A. O’Connor, Jennifer Park, Thomas Kaley, Brie Kezlarian, Marcia Edelweiss, T. Jonathan Yang, Wungki Park, Diane Lauren Reidy, Anna M. Varghese, Kenneth H. Y...> ;Pancreatology. 2021 Feb 6
• 47 citations
  Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors
  Andrew Dunbar, Kelly L. Bolton, Sean M. Devlin, Francisco Sanchez-Vega, Jianjiong Gao, Jodi V. Mones, Jonathan Wills, Daniel Kelly, Mirko Farina, Keith B. Cordner, You...> ;Blood. 2021 Apr 15
• 42 citations
  Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma
  Caitlin A. McIntyre, Sharon A. Lawrence, Allison Richards, Joanne F. Chou, Winston Wong, Marinela Capanu, Michael F. Berger, Mark T.A. Donoghue, Kenneth H. Yu, Anna M....> ;Cancer. 2020 Sep 1
• Join now to see all

Abstracts/Posters

• Extended Mutational Profiling By MSK-IMPACTTM Identifies Mutations Predicting Thromboembolic Risk in Patients with Solid Tumor MalignancyClinically Relevant Abstract
  Wungki Park, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• An Inflammation Paradox: Obesity and Neutrophil-Lymphocyte Ratio in Immunotherapy.
  Park W, Florou V, Torres A, Saravia D, Algaze S, and Lopes G, AACR Annual Meeting, Chicago, IL, 1/1/2018
• High Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) and its Reactive Increase as Better Predictors of for Poor Clinical Outcomes Compared To Tumor Mutation Burden (...
  Florou V, Park W, Torres A, Algaze S, Saravia D, Kwon D, Hosein P, Merchan J, Wilky B, Lockhart C, Lopes G, ASCO Annual Meeting, Chicago, IL, 1/1/2018
• Predicting outcomes of patients with advanced non-small cell lung cancer treated with PD-1/PDL-1 inhibitors: independent international validation of the iSEND model.
  Park W, Mezquita L, Okabe N, Kwon D, Saravia D, Chae Y, Desai A, Planchard D, Caramella C, Mudad R, Jahanzeb M, Suzuki H, Besse B, Lopes G, ASCO Annual Meeting, Chicago, IL, 1/1/2018
• Neutrophil-Lymphocyte-Ratio complements the prediction ability of PD-L1 expression in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibit...
  Saravia D, Okabe N, Park W, Kwon D, Mezquita L, Chae Y, Mudad R, Jahanzeb M, Suzuki H, Besse B, Lopes G, ASCO Annual Meeting, Chicago, IL, 1/1/2018
• A Phase II Trial of Axitinib Plus Pembrolizumab for Patients with Advanced Alveolar Soft Part Sarcoma (ASPS) and Other Soft Tissue Sarcomas (STS).
  Wilky B, Trucco M, Kolonias D, Wieder E, Subhawong T, Rosenberg A, Kwon D, Park W, Florou V, Kerr D, Sfakianaki E, Merchan J, Komanduri K, Trent J, ASCO Annual Meeting, Chicago, IL, 1/1/2018
• Oncolytic virotherapy is an effective immunotherapy: meta-analysis for clinical trials.
  Park W, Algaze S, Abi Aad S, Elias R, Kwon D, Chavez V, Jing Y, Acquavella N, Merchan J, ASCO Annual meeting, Chicago, IL, 1/1/2017
• Outcomes of biliary stents in advanced pancreatic cancer in the era of FOLFIRINOX therapy.
  Park W, Mankal P, O’Reilly E, ASCO Annual meeting, Chicago, IL, 1/1/2017
• Neutrophil-Rich Inflammation and PD1/PD-L1 inhibitor Resistance in Advanced Non-Small Cell Lung Cancer Patients.
  Park W, Algaze S, Florou V, Saravia D, Kwon D, and Lopes G, SITC Annual Meeting, Washington, DC, 1/1/2017
• iSEND May Predict Clinical Outcomes for Advanced NSCLC Patients on PD-1/PD-L1 inhibitors but Not Chemotherapies or Targeted Kinase Inhibitors.
  Park W, Kwon D, Desai A, Florou V, Saravia D, Warsch J, Chae Y, Ishkanian A, Jahanzeb M, Mudad R, and Lopes G, WCLC Annual Meeting, Yokohama, Japan, 1/1/2017
• Correlating iSEND and Tumor Mutation Burden (TMB) with Clinical Outcomes of Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients on Nivolumab
  Park W, Lopes G, Kwon D, Florou V, Saravia D, Chae Y, Warsch J, Ishkanian A, Jahanzeb M, and Mudad R, WCLC Annual Meeting, Yokohama, Japan, 1/1/2017
• Clinicopathologic feature and outcome of appendiceal goblet cell carcinoid and neuroendocrine tumor.
  Park W, Vallabhaneni G, Martin L, Adsay V, Staley C, Maithel S, Wang Z, Chen Z, El-Rayes B, Bekaii-Saab T, ASCO Annual Meeting, IL, 1/1/2012
• A Loss of Function Genetic Screen Identifies Determinants of Sensitivity to PARP Inhibitor ABT-888 in Pancreatic Cancer.
  Park W, Pantazides B, El-Rayes B, Shelton J, Yu D, Landry J, International Journal of Radiation Oncology, IL, 1/1/2012
• Join now to see all

Lectures

• Homologous recombination deficiency (HRD): A biomarker for first-line (1L) platinum in advanced pancreatic ductal adenocarcinoma (PDAC). 
  2019 ASCO Annual Meeting - 6/1/2019
• Predicting outcomes of advanced non-small cell lung cancer patients treated with PD-1/PDL-1 inhibitors: Independent international validation of the iSEND model. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• ASCO Review – Updates & Advances in Cancer Therapy 
  Ft. Lauderdale, FL - 1/1/2017
• The Basics of Lung Cancer 
  Miami, FL - 1/1/2017
• Join now to see all